Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Parkin anticorps (AA 361-465)

PARK2 Reactivité: Rat WB, ELISA, IF (cc), IF (p), IHC (p), FACS, IHC (fro) Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN735578
  • Antigène Voir toutes Parkin (PARK2) Anticorps
    Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
    Épitope
    • 17
    • 17
    • 15
    • 9
    • 9
    • 7
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 361-465
    Reactivité
    • 78
    • 27
    • 27
    • 6
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    Rat
    Hôte
    • 103
    • 7
    • 1
    Lapin
    Clonalité
    • 104
    • 7
    Polyclonal
    Conjugué
    • 56
    • 6
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 1
    Cet anticorp Parkin est non-conjugé
    Application
    • 99
    • 39
    • 38
    • 38
    • 22
    • 20
    • 17
    • 17
    • 8
    • 5
    • 4
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))
     Réactivité croisée
    Rat
    Homologie
    Human,Mouse,Pig
    Purification
    Purified by Protein A.
    Immunogène
    KLH conjugated synthetic peptide derived from human E3 ubiquitin-protein ligase parkin
    Isotype
    IgG
    Top Product
    Discover our top product PARK2 Anticorps primaire
  • Indications d'application
    WB 1:300-5000
    ELISA 1:500-1000
    FCM 1:20-100
    IHC-P 1:200-400
    IHC-F 1:100-500
    IF(IHC-P) 1:50-200
    IF(IHC-F) 1:50-200
    IF(ICC) 1:50-200
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 μg/μL
    Buffer
    0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
    Agent conservateur
    ProClin
    Précaution d'utilisation
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
    Date de péremption
    12 months
  • Li, Zhang, Wang, Liu, Yang, Liu, Lu: "Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant ?-synuclein." dans: Phytomedicine : international journal of phytotherapy and phytopharmacology, Vol. 21, Issue 5, pp. 704-11, (2014) (PubMed).

  • Antigène
    Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
    Autre désignation
    PARK2 (PARK2 Produits)
    Synonymes
    anticorps CG10523, anticorps Dmel\\CG10523, anticorps Dpark, anticorps SD01679, anticorps dpk, anticorps AR-JP, anticorps LPRS2, anticorps PDJ, anticorps PRKN, anticorps Park, anticorps Prkn, anticorps si:ch211-123f21.1, anticorps zgc:112390, anticorps pdr-1, anticorps PARK2, anticorps parkin, anticorps parkin RBR E3 ubiquitin protein ligase, anticorps Parkinson disease (autosomal recessive, juvenile) 2, parkin, anticorps park, anticorps PRKN, anticorps Prkn, anticorps prkn, anticorps CpipJ_CPIJ014867, anticorps Park2
    Sujet

    Synonyms: PDJ, PRKN, AR-JP, LPRS2, E3 ubiquitin-protein ligase parkin, Parkinson juvenile disease protein 2, Parkinson disease protein 2, PARK2

    Background: Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, TOMM2, USP3, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria (mitophagy) by the ubiquitination of mitochondrial proteins such as TOMM2, RHOT1/MIRO1 and USP3 (PubMed:24896179). Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome, possibly playing a role in the regulation of neuron death. Limits the production of reactive oxygen species (ROS). Regulates cyclin-E during neuronal apoptosis. In collaboration with CHPF isoform 2, may enhance cell viability and protect cells from oxidative stress. Independently of its ubiquitin ligase activity, protects from apoptosis by the transcriptional repression of p53/TP53. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. May represent a tumor suppressor gene.

    ID gène
    5071
    UniProt
    O60260
    Pathways
    Autophagy, Ubiquitin Proteasome Pathway
Vous êtes ici:
Support technique